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Background: Lupus nephritis (LN) is characterized by intrarenal infiltration
and activation of T-lymphocytes. Since T-bet and GATA-3 are the key
transcription factors mastering the differentiation of Th1 and Th2 lymphocytes,
we studied their intrarenal expression and correlated their expression with the
severity of kidney lesions in LN patients. Methods: Glomerulus and
tubulointerstitium were isolated from the snap-frozen biopsied kidney tissue
of 37 LN patients by laser capture microdissection. The mRNA expression of
T-bet and GATA-3 were studied by real-time quantitative polymerase chain
reaction. Results: T-bet expression in glomerulus and tubulointerstitium of LN
patients were 53.9 ( 9.9 and 23.8 ( 6.7 folds higher than the normal kidney
controls. In contrast, GATA-3 expression in glomerulus was 1.9 ( 0.3 folds
elevated, but depressed by 3.0 ( 0.5 folds in tubulointerstitium as compared to
normal control. Both T-bet and GATA-3 showed a strong internal correlation
between their expression in glomerulus and tubulointerstitium (r = 0.59 and
r = 0.69, p < 0.001 for both). The T-bet-to-GATA-3 expression ratio in
glomerulus significantly correlated with serum creatinine (r = 0.36, p = 0.03),
glomerular filtration rate (r = –0.41, p = 0.01) and degree of renal fibrosis by
morphometry (r = 0.40, p = 0.04). In addition, the degree of glomerulosclerosis
and cortical fibrosis inversely correlated with GATA-3 expression in glomerulus
(r = –0.47, p = 0.006) and tubulointerstitium (r = –0.44, p = 0.01) respectively.
The degree of leukocyte infiltration significantly correlated with
tubulointerstitium expression of T-bet (r = 0.44, p = 0.01). The total histologic
chronicity index inversely correlated with GATA-3 expression in glomerulus
(r = –0.42, p = 0.02) and tubulointerstitium (r = –0.37, p = 0.03). Conclusions:
LN patients have a shift of T-bet/GATA-3 expression in the kidneys, and the
expression correlates with the severity of histologic involvement. Our result
suggests that Th1/Th2 imbalance may be important in the pathogenesis of renal
damage in LN.
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Background: Mannose binding lectin (MBL), a calcium dependent C-type
lectin, is an important first line defence mechanism to protect the body from
infection, by its capability to activate the complement system and phagocytosis.
A low serum MBL may lead to an opsonic defect, which impairs phagocytosis
by polymorphonuclear leukocytes. Study has shown low serum MBL level was
associated with a higher incidence of spontaneous bacterial peritonitis in chronic
viral hepatitis patients. Peritoneal dialysis (PD) related peritonitis is one of the
major factor causing technique failure and mortality in patients on long-term
dialysis. It is important to investigate any risk factor for peritonitis and related
complication. Herein, we study any association between the peritonitis rate
and MBL gene mutation in our long-term PD patients and investigate whether
patients with peritonitis related technique failure associated with higher rate of
MBL gene mutation. Methods: Long-term PD patients were recruited from
two dialysis centers. Patients with repeated episodes of peritonitis classified as
peritonitis group (RP). Patients without any history of peritonitis but having
been on PD for more than 2 years were recruited as non-peritonitis group (NP).
It was because the peritonitis rate was average once every 24 patient-months in
our centers. For patients who developed technique failure secondary to
peritonitis, currently on long-term hemodialysis were also recruited as HD
group. Blood samples and peritoneal fluid were collected for analysis. Serum
and peritoneal MBL levels were measured by the enzyme-linked immunoassay.
MBL gene mutation at codons 52, 54 and 57 was detected by polymerase chain
reaction assay. Results: There were 68 patients (NP), 51 patients (RP) and 46
patients (HD) recruited with mean age of 56.5 ( 15.8 years (M = 87). Thirty-
four patients (21%) were diabetic. The median of duration of PD was 4.43
years (range, 0.8–9.9). There were 35 patients (21.2%) who had codon 54
mutations, but no patient had codons 52 and 57 gene mutations. Serum (575.6
( 381 ng/mL) and peritoneal (36.2 ( 11.8 ng/mL) MBL levels of patients with
mutations were significant lower compared to other patients without mutations
(2,311 ( 1,030 ng/mL and 54.0 ( 26.6 ng/mL, p < 0.001). Nevertheless, the
mutation rate of codon 54 among different study groups was similar (NP:
23.5% vs RP: 23.5% vs HD: 15.2%). Conclusions: Patients with MBL gene
mutation had a lower level of serum and peritoneal MBL levels. However, it
did not suggest a higher incidence of peritonitis or technique failure associated
with MBL gene mutation.
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Background: Fluid overload increases chronic dialysis patient morbidity and
mortality. A CQI project on improving fluid compliance in PD patients was
done in 2002 to 2003. Objectives: To identify the group of PD patients with
fluid compliance problems, to explore the causes of fluid non-compliance, and
to develop strategies to improve fluid compliance. Methods: All the PD patient
records were reviewed. Patients with history of fluid overload were identified.
A checklist was developed to collect information on patient physical status and
eating habits. All the identified patients were arranged to have intensive patient
education program on fluid compliance. Renal nurses performed periodic
assessment on the patients. Number of episodes of fluid overload and the extra
dialysis required due to poor fluid compliance were compared in the 12 months
before and after the CQI program. Results: Ninety-nine (35.5%) out of the
279 chronic PD patients were identified to have a history of fluid overload.
Sixty-nine patients had stayed in the CQI program for 12 months. Signif icantly
fewer patients had ankle edema after the CQI program (p = 0.018). When
compared with the 12 months before and after the CQI program, the group of
patients required less extra dialysis (p = 0.01) and there was a decrease in
episodes of fluid overload due to poor fluid compliance (p < 0.001).
Conclusions: One-third of the chronic PD patients experienced fluid overload.
A majority of the fluid overload patients underestimated their daily total fluid
intake. Appropriate patient education such as dietary counseling and
reinforcement on educating patients on the harmful effects of fluid overload
can improve fluid compliance in chronic peritoneal dialysis patients.
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Background: We conducted a double-blind, randomized, placebo-controlled
multicenter study on the use of the angiotensin II receptor block er (ARB)
valsartan 80–160 mg in reducing proteinuria and retarding the progression of
renal failure in patients with IgA nephropathy. Methods: One hundred and
nine patients, from six centers, with IgA nephropathy, characterized by either
(i) proteinuria more than 1 g daily and serum creatinine less than 250 +mol/L,
or (ii) serum creatinine between 120 and 250 +mol/L irrespective of proteinuria
magnitude were randomized to receive either valsartan 80 mg (titrated up to
160 mg for blood pressure control) or placebo for 104 weeks. Additional
antihypertensives were allowed to control blood pressure in both groups.
Results: Fifty-four patients [(41 females) mean age 40.2 ( 9.2 years] were
randomized to active treatment, and the placebo group consisted of 55 patients
[(38 females) mean age 40.5 ( 9.2 years]. No discernible difference was noted
in the baseline creatinine clearance or proteinuria between the treatment and
placebo groups. Baseline blood pressure and lipid profile were also comparable.
After adjustment for the blood pressure and baseline proteinuria, annual decline
in glomerular filtration rate was 4.3 mL/min/year (95% CI 0.2–8.6 mL/min/
year, p = 0.038) slower in the active treatment group after 52 weeks. Treatment
benefit was maintained until the end of study period, with the glomerular
filtration rate annual decline difference being 4.6 mL/min/year (p = 0.028).
After 104 weeks, the proteinuria of the treatment group reduced from 1.8 (
1.2 to 1.2 ( 1.2 g/day (p = 0.03), and from 2.3 ( 1.7 to 2.0 ( 1.7 g/day in the
placebo group (p = 0.72). Valsartan treatment resulted in significant reduction
in proteinuria compared with placebo (p = 0.001). No severe adverse event was
encountered in both treatment and placebo groups. Conclusions: The
angiotensin II receptor blocker valsartan is a safe and effective treatment that
leads to slower renal deterioration and more reduction in proteinuria in patients
with IgA nephropathy.
